New Agent Reduces Eye Bulging in Graves’ Orbitopathy, Offering New Hope for Patients | oneGRAVESvoice

welcome to oneGRAVESvoice

- a positively charged Graves' disease and thyroid eye disease community.
  • join today!

New Agent Reduces Eye Bulging in Graves’ Orbitopathy, Offering New Hope for Patients


An experimental human monoclonal antibody dramatically reduced the most debilitating symptoms of Graves’ orbitopathy, including proptosis and double vision, giving new hope to patients that a treatment for thyroid eye disease may finally be within reach, according to a speaker at the AACE Annual Scientific and Clinical Congress.

According to new phase 3 data from the OPTIC trial presented here, adults with active Graves’ orbitopathy treated with teprotumumab (Horizon Pharma) for 21 weeks experienced an average proptosis reduction of 2.82 mm at 24 weeks compared with an average of 0.54 mm for those assigned to placebo, with between-group differences in proptosis reduction observed at all study time points, according to Raymond Douglas, MD, PhD, Director of the orbital and thyroid eye disease program at Cedars-Sinai Medical Center. Other symptoms associated with the disease, including inflammation, pain, swelling and redness, were also reduced for patients assigned teprotumumab vs. placebo, he said.

New Agent Reduces Eye Bulging In Graves’ Orbitopathy, Offering New Hope For Patients